Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
Unternehmen & Branche
| Name | MapLight Therapeutics, Inc. |
|---|---|
| Ticker | MPLT |
| CIK | 0001770069 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 23,8 Mio. USD |
| Beta | -2,79 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -161,152,000 | -18.56 | 479,512,000 | 458,372,000 | |
| 2025-09-30 | 10-Q | -29,418,000 | -37.18 | 257,222,000 | -274,177,000 | |
| 2025-06-30 | 10-Q | -29,846,000 | -245,063,000 | |||
| 2025-03-31 | 10-Q | -22,340,000 | -215,829,000 | |||
| 2024-12-31 | 10-K | -77,580,000 | -105.38 | 136,916,000 | -193,628,000 | |
| 2024-09-30 | 10-Q | -19,016,000 | -25.08 | -172,370,000 | ||
| 2024-06-30 | 10-Q | -18,400,000 | -154,328,000 | |||
| 2024-03-31 | 10-Q | -18,935,000 | -135,997,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Foff Erin Pennock | Officer, Chief Medical Officer | Open Market Sale | -288 | 27.01 | -7,778.88 | -0,3% | |
| 2026-04-16 | Hanson Kristopher | Officer, General Counsel | Open Market Sale | -73 | 27.01 | -1,971.73 | -0,1% | |
| 2026-04-16 | Setia Vishwas | Officer, Chief Financial Officer | Open Market Sale | -87 | 27.49 | -2,391.63 | -0,1% | |
| 2026-04-16 | Setia Vishwas | Officer, Chief Financial Officer | Open Market Sale | -29 | 27.01 | -783.29 | 0,0% | |
| 2026-04-16 | Lillie James Woodruff | Officer, Chief Scientific Officer | Open Market Sale | -2,097 | 27.49 | -57,646.53 | -1,9% | |
| 2026-04-16 | Lillie James Woodruff | Officer, Chief Scientific Officer | Open Market Sale | -686 | 27.01 | -18,528.86 | -0,6% | |
| 2026-04-16 | Kroeger Christopher A. | Director, Officer, Chief Executive Officer | Open Market Sale | -7,575 | 27.49 | -208,236.75 | -6,9% | |
| 2026-04-16 | Kroeger Christopher A. | Director, Officer, Chief Executive Officer | Open Market Sale | -2,477 | 27.01 | -66,903.77 | -2,2% | |
| 2026-04-16 | Foff Erin Pennock | Officer, Chief Medical Officer | Open Market Sale | -881 | 27.49 | -24,218.69 | -0,8% | |
| 2026-04-16 | Hanson Kristopher | Officer, General Counsel | Open Market Sale | -225 | 27.49 | -6,185.25 | -0,2% | |
| 2026-04-15 | GILLIS JONATHAN | Officer, CAAO and PAO | Open Market Sale | -3,590 | 26.61 | -95,529.90 | -3,2% | |
| 2026-04-15 | Malenka Robert C. | Director | Open Market Sale | -8,593 | 26.90 | -231,151.70 | -7,6% | |
| 2026-04-15 | Lillie James Woodruff | Officer, Chief Scientific Officer | Open Market Sale | -1,730 | 26.82 | -46,398.60 | -1,5% | |
| 2026-04-15 | Hanson Kristopher | Officer, General Counsel | Open Market Sale | -1,529 | 26.80 | -40,977.20 | -1,4% | |
| 2026-04-15 | Kreitzer Anatol | Officer, Chief Discovery Officer | Open Market Sale | -3,316 | 26.61 | -88,238.76 | -2,9% | |
| 2026-04-15 | Foff Erin Pennock | Officer, Chief Medical Officer | Open Market Sale | -2,044 | 26.84 | -54,860.96 | -1,8% | |
| 2026-04-15 | Setia Vishwas | Officer, Chief Financial Officer | Open Market Sale | -2,806 | 26.87 | -75,397.22 | -2,5% | |
| 2026-04-15 | Kroeger Christopher A. | Director, Officer, Chief Executive Officer | Open Market Sale | -9,135 | 26.93 | -246,005.55 | -8,1% | |
| 2026-02-24 | Malenka Robert C. | Director | Open Market Sale | -736 | 18.15 | -13,358.40 | -0,4% | |
| 2026-02-23 | Malenka Robert C. | Director | Open Market Sale | -10,788 | 18.39 | -198,391.32 | -6,6% | |
| 2026-02-23 | Malenka Robert C. | Director | Open Market Sale | -476 | 19.06 | -9,072.56 | -0,3% | |
| 2026-02-20 | Malenka Robert C. | Director | Open Market Sale | -2,195 | 18.03 | -39,575.85 | -1,3% | |
| 2026-02-20 | Pavlov George | Director | Open Market Purchase | 9,920 | 17.86 | 177,171.20 | +5,9% | |
| 2026-02-19 | Pavlov George | Director | Open Market Purchase | 4,422 | 17.57 | 77,694.54 | +2,6% | |
| 2026-02-18 | Pavlov George | Director | Open Market Purchase | 10,658 | 17.48 | 186,301.84 | +6,2% | |
| 2026-02-13 | Malenka Robert C. | Director | Open Market Sale | -12,116 | 18.21 | -220,632.36 | -7,3% | |
| 2026-02-11 | Malenka Robert C. | Director | Open Market Sale | -241 | 18.00 | -4,338.00 | -0,1% | |
| 2026-02-10 | Malenka Robert C. | Director | Open Market Sale | -6,622 | 18.12 | -119,990.64 | -4,0% | |
| 2026-02-10 | Garnett Timothy John | Director | Open Market Purchase | 14,124 | 17.89 | 252,678.36 | +8,3% | |
| 2026-02-03 | Malenka Robert C. | Director | Open Market Sale | -1 | 18.00 | -18.00 | 0,0% | |
| 2026-02-02 | Malenka Robert C. | Director | Open Market Sale | -7,039 | 18.02 | -126,842.78 | -4,2% | |
| 2026-01-30 | Malenka Robert C. | Director | Open Market Sale | -6,612 | 18.11 | -119,743.32 | -4,0% | |
| 2026-01-29 | Malenka Robert C. | Director | Open Market Sale | -21,262 | 18.55 | -394,410.10 | -13,0% | |
| 2026-01-28 | Malenka Robert C. | Director | Open Market Sale | -5,860 | 18.61 | -109,054.60 | -3,6% | |
| 2026-01-28 | Malenka Robert C. | Director | Open Market Sale | -664 | 19.05 | -12,649.20 | -0,4% | |
| 2025-10-28 | Novo Holdings A/S | 10% Owner | Open Market Purchase | 952,941 | 17.00 | 16,199,997.00 | +535,0% | |
| 2025-10-28 | Catalyst4, Inc. | 10% Owner | Open Market Purchase | 5,441,176 | 17.00 | 92,499,992.00 | +3054,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.